Coverage
AstraZeneca PLC said its experimental drug baxdrostat significantly lowered blood pressure in patients with a hard-to-treat form of hypertension, meeting the main goal of a late-stage trial.
AstraZeneca PLC and Daiichi Sankyo said their drug Datroway significantly improved survival for patients with an aggressive form of breast cancer in a late-stage study.
AstraZeneca PLC said its cancer drug Enhertu, developed with Daiichi Sankyo, showed a significant improvement over the standard treatment in a late-stage trial for patients with a high-risk form of early breast cancer.
AstraZeneca PLC on Monday announced plans to directly list its ordinary shares on the New York Stock Exchange, a move aimed at attracting a broader base of global investors and accessing deeper capital pools.
AstraZeneca PLC said its drug Koselugo won a key European regulatory backing for use in adults, a positive development for the company following recent setbacks in its drug pipeline.
AstraZeneca PLC said its drug Tezspire, developed with Amgen Inc., won a key European regulatory backing for a new use, a positive development for the company following recent trial setbacks.
Filings
| Filing | Date |
|---|---|
| Enhertu improved PFS in HER2-low and ultralow | 29 Apr 2024 |
| Truqap recommended for EU breast cancer approval | 29 Apr 2024 |
| 1st Quarter Results | 25 Apr 2024 |
| AstraZeneca increases 2024 dividend by 7% | 11 Apr 2024 |
| Result of AGM | 11 Apr 2024 |
| Enhertu approved in US for HER2+ solid tumours | 8 Apr 2024 |
| Imfinzi improved OS & PFS in limited-stage SCLC | 5 Apr 2024 |
| FDA accepts Dato-DXd BLA for breast cancer | 2 Apr 2024 |
| Voydeya approved in US | 2 Apr 2024 |
| Total Voting Rights | 2 Apr 2024 |
| Ultomiris approved in the US for NMOSD | 25 Mar 2024 |
| AstraZeneca to acquire Fusion | 19 Mar 2024 |